EFFICACY OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE IB–IIA CERVICAL CANCER
DOI:
https://doi.org/10.15407/oncology.2025.04.247Keywords:
cervical cancer, surgical treatment, neoadjuvant chemotherapy, chemoradiation therapy, quality of lifeAbstract
Summary. Aim: to evaluate the effectiveness of neoadjuvant chemotherapy (NACT) in patients with stage IB1–IIA cervical cancer. Object and methods: the study included 93 patients with stage IB–IIA cervical cancer who received treatment and were followed up at the Prykarpattia Clinical Oncology Center during the period from 2018 to 2024. The diagnosis of cervical cancer was verified histologically based on biopsy data of the primary tumor. Two groups were compared: group I (n = 64) – patients received chemoradiation treatment in the postoperative period; group II (n = 29) – patients received NACT before surgical treatment. The effectiveness of NACT was assessed by the frequency of postoperative complications, quality of life criteria, and recurrence-free and overall survival. Results: the use of NACT followed by surgical treatment of patients with stage ІВ-ІІА cervical cancer, compared with surgical treatment and postoperative chemoradiotherapy, improves the quality of life and reduces disease recurrence. The combination of cisplatin with paclitaxel demonstrates a high level of complete and partial response and the possibility of further radical surgical treatment without the appointment of a postoperative course of chemoradiotherapy. Conclusions: NACT in patients with stage IB–IIA cervical cancer demonstrates high clinical effectiveness. In most cases, this allows for radical surgical treatment and reduces the need for postoperative radiotherapy.
References
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108. https://doi.org/10.3322/caac.21262.
Fedorenko ZP, Sumkina OV, Horokh YeL, et al. Cancer in Ukraine, 2020–2021: Incidence, mortality, and performance indicators of the oncology service. Bulletin of the National Cancer Registry of Ukraine, 2022; 23. 129р. http://www.ncru.inf.ua/publications/BULL_23/index_e.htm
Abou-Taleb HA, Koshiyama M, Matsumura N, et al. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. J Int Med Res 2016; 44 (2): 346–56. https://doi.org/10.1177/0300060515591858.
Benedetti Panici P, Palaia I, Marchetti C, et al. Dose-dense neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: A phase II study. Oncology 2015; 89 (2): 103–10. https://doi.org/10.1159/000381461.
Maneo A, Chiari S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol 2008; 111 (3): 438–43. https://doi.org/10.1016/j.ygyno.2008.08.023.
Li R, Lu S, Xi J, et al. Prognostic value of response to neoadjuvant chemotherapy before surgery for patients with stage IB2/IIA2 cervical cancer. Gynecol Oncol 2013; 128 (3): 524–9. https://doi.org/10.1016/j.ygyno.2012.11.006.
Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery alone for cervical cancer. Cochrane Database Syst Rev 2012; 12 (12): CD007406. https://doi.org/10.1002/14651858.CD007406.pub3.
Yin M, Zhao F, Lou G, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer 2011; 21 (1): 92–9. https://doi.org/10.1111/IGC.0b013e3181fe8b6e.
Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 2013; 39 (2): 115–24. https://doi.org/10.1016/j.ejso.2012.09.003.
Benedetti-Panici PL, Zullo MA, Muzii L, et al. The role of neoadjuvant chemotherapy followed by radical surgery in the treatment of locally advanced cervical cancer. Eur J Gynecol Оncol 2003; 24 (6): 467–70.
